IP Library Granted Patent US 10,111,938
Granted Patent B2
US 10,111,938 · App. 15/067,515 · Granted Oct 30, 2018

Injection paradigm for administration of botulinum toxins

Inventors: Andrew M. Blumenfeld (Del Mar, CA); Mitchell F. Brin (Newport Beach, CA)
Assignee: Allergan, Inc.
A61K38/4893A61K9/0019C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,111,938
App. No.
15/067,515
Granted
Oct 30, 2018
Kind
B2
Abstract

Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.

Claims (24)

1. A method for alleviating or reducing the occurrence of a headache in a patient with chronic migraine headaches, the method comprises:

localizing one or more administration targets;

isolating the one or more administration targets; wherein the isolating step isolates the one or more administration targets from an adjacent area; thereby preventing or minimizing unwarranted adverse effects;

administering a therapeutically effective amount of a clostridial toxin to the one or more isolated administration targets;

wherein the one or more administration targets comprises the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles;

wherein the administrating step is by injection and wherein the administering step comprises limiting the injection to a defined tissue depth and injection angle; and wherein the administrating to the corrugator muscle comprises targeting the belly of the corrugators and injecting superficially at a 90° angle into the belly of the corrugator muscles.

2. The method of claim 1 , wherein the isolating the corrugator muscle comprises providing a patient instructions to furrow her/his brow, palpating and pinching the corrugator muscle, holding the corrugator muscle between the thumb and index finger.

3. The method of claim 1 , wherein the isolating the procerus muscle comprises providing patient instructions to furrow her/his brow, using the resulting vertical and horizontal lines as orientation lines.

4. The method of claim 1 , wherein the administering to the procerus muscle comprises targeting the belly of the procerus muscle, injecting superficially at a 90° angle into the procerus, and controlling the penetration depth of the needle such that it remains above the periosteum.

5. The method of claim 1 , wherein the isolating the frontalis muscle comprises providing a patient instructions to raising her/his eyebrows and skin over the root of the nose in an attempt to create an expression of surprise and identifying the upper third of the forehead.

6. The method of claim 1 , wherein the administrating step to the frontalis comprises angling the needle superiorly at a 45° angle into the frontalis muscle, and injecting superficially by controlling the penetration depth of the needle such that it remains above the periosteum.

7. The method of claim 1 , wherein the localizing the cervical paraspinal muscles comprises providing instructions to the patient to sit upright, with his/her head in a neutral position, visualizing a line across the patient's neck about 2 fingerbreadths down from the occipital protuberance.

8. The method of claim 7 , wherein the administrating step to the cervical paraspinal comprises injecting superficially at a 45° angle above the visualized line about 2 fingerbreadths down from the patient's occipital protuberance.

9. The method of claim 1 , wherein the administrating to the trapezius muscle comprises injecting horizontally to the trapezius muscle.

10. The method of claim 1 , wherein the administrating to the trapezius muscle comprises injecting the supraclavicular portion of the muscle, lateral to the necklace line and medial to the deltoid/acromion joint.

11. The method of claim 1 , wherein the clostridial toxin is a botulinum toxin.

12. A method for minimizing adverse effects associated with the administration of a clostridial toxin for treating or alleviating a headache in a patient with chronic migraine, the method comprises locating one or more administration targets, isolating the one or more administration targets, administering a therapeutically effective amount of a clostridial toxin to the one or more isolated administration targets; wherein the administrating step is by injection and wherein the administering step comprises limiting the injection to a defined tissue depth and injection angle; wherein the isolating step isolates the one or more administration targets from an adjacent area; thereby minimizing adverse effects; wherein the one or more administration targets comprise the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles;

and wherein the administrating to the corrugator muscle comprises targeting the belly of the corrugators and injecting superficially at a 90° angle into the belly of the corrugator muscles.

13. The method of claim 12 , wherein the adverse effects comprise ptosis, neck pain and/or weakness, headache, or combinations thereof.

14. The method of claim 12 , wherein the clostridial toxin is a botulinum toxin.

15. A method for improving efficacy of headache treatment by a clostridial toxin in a patient in need thereof by minimizing one or more adverse effects associated with clostridial toxin administration, comprising localizing one or more administration targets, isolating the one or more administration targets, administering a therapeutically effective amount of the clostridial toxin to the isolated one or more administration targets; wherein the isolating step isolates the one or more administration targets from an adjacent area; wherein the administrating step is by injection and wherein the administering step comprises limiting the injection to a defined tissue depth and injection angle; thereby preventing or minimizing unwarranted adverse effects and improving efficacy of headache treatment; wherein the one or more administration targets comprise the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles; and wherein the administrating to the corrugator muscle comprises targeting the belly of the corrugators and injecting superficially at a 90° angle into the belly of the corrugator muscles.

16. The method of claim 15 , wherein the adverse effects comprise ptosis, neck pain, neck weakness, headaches, or combinations thereof.

17. The method of claim 15 , further comprising evaluating the patient of manifestation of the one or more adverse effects prior to the localizing, isolating and administrating steps.

18. The method of claim 15 , wherein the clostridial toxin is a botulinum toxin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2020
From: BLUMENFELD, ANDREW M.; BRIN, MITCHELL F.
To: ALLERGAN, INC.
Reel/Frame 053089/0593 →
Continuity (2)
Provisional Application 62132689 · Mar 13, 2015
Related Publication 20160263202A1 · Sep 15, 2016
Cited By (2)
US 12,364,740 US 12,533,400